Vesicles | Jotup

EVerZom Raises €1.1M to Industrialize Its Exosome Biomanufacturing Platform

Retrieved on:

Tuesday, December 1, 2020

Research, Genetics, Clinical trials, Stem cells, Biotechnology, Other Health, Health, Science, Oncology, Branches of biology, Vesicles, Exosome, Bioproduction

EVerZom, a biopharmaceutical company specialized in the bioproduction of exosomes, announced today that it has raised 1.1 million in funding from institutional and private investors to develop its exosome bioproduction platform.

Key Points:

EVerZom, a biopharmaceutical company specialized in the bioproduction of exosomes, announced today that it has raised 1.1 million in funding from institutional and private investors to develop its exosome bioproduction platform.
This funding will speed up the platform development and scale-up, with the objective to allow routine clinical grade production by 2022.
This technology and the know-how developed around exosomes allows EVerZom to offer a scalable and reproducible exosome production process with robust quality controls.
"We are delighted with this financing opportunity, which will enable us to industrialize our proprietary technology and meet the growing demand of the exosome market.

Vesigen Therapeutics Names Lucio Iannone to Board of Directors

Retrieved on:

Tuesday, December 1, 2020

Branches of biology, Biology, Cell biology, Cells, Extracellular vesicle, Vesicles, Bayer

CAMBRIDGE,Mass., Dec. 1, 2020 /PRNewswire/ --Vesigen Therapeutics, Inc., a biotechnology company pioneering a novel extracellular vesicle delivery technology to develop transformative therapeutics, today announced the addition of Dr. Lucio Iannone, Senior Director of Venture Investments at Leaps by Bayer, to its Board of Directors.

Key Points:

CAMBRIDGE,Mass., Dec. 1, 2020 /PRNewswire/ --Vesigen Therapeutics, Inc., a biotechnology company pioneering a novel extracellular vesicle delivery technology to develop transformative therapeutics, today announced the addition of Dr. Lucio Iannone, Senior Director of Venture Investments at Leaps by Bayer, to its Board of Directors.
Iannone joins Gerald Chan, Chairman, and Stephen Bruso of Morningside Ventures and Juergen Eckhardt of Leaps by Bayer on Vesigen's Board.
Iannone was as an integral figure in the financing, and currently serves as a board member, for Khloris Biosciences, Pyxis Oncology, Immunitas Therapeutics, eGenesis, Azitra, and Axxam.
Vesigen Therapeutics is a biotechnology company advancing groundbreaking therapies directed to intracellular targets using a fusogenic extracellular vesicle delivery technology.

Evox Therapeutics expands its existing exosome patent portfolio

Retrieved on:

Tuesday, November 24, 2020

Branches of biology, Vesicles, Exosome, Extracellular vesicle, European Patent Office

OXFORD, England, Nov. 24, 2020 /PRNewswire/ -- Evox Therapeutics Ltd ('Evox' or the 'Company'), a leading exosome therapeutics company, is pleased to announce that the Company has been granted another key patent by the European Patent Office (EPO).

Key Points:

OXFORD, England, Nov. 24, 2020 /PRNewswire/ -- Evox Therapeutics Ltd ('Evox' or the 'Company'), a leading exosome therapeutics company, is pleased to announce that the Company has been granted another key patent by the European Patent Office (EPO).
This new grant reinforces the Company's leading position within field of exosome therapeutics and adds to the growing number of foundational patent families within the Evox IP portfolio.
Dr Antonin de Fougerolles, Chief Executive Officer of Evox, commented:
"We are pleased to have been granted another important patent within our rapidly growing therapeutic exosome patent estate.
Evox Therapeutics is a privately held, Oxford-based biotechnology company focused on harnessing and engineering the natural delivery capabilities of extracellular vesicles, known as exosomes, to develop an entirely new class of therapeutics.

Codiak BioSciences to Present at the Evercore ISI 3rd Annual HealthCONx Conference

Retrieved on:

Monday, November 23, 2020

Branches of biology, Vesicles, Exosome

CAMBRIDGE, Mass., Nov. 23, 2020 (GLOBE NEWSWIRE) -- Codiak BioSciences, Inc. (NASDAQ: CDAK), a clinical-stage company focused on pioneering the development of exosome-based therapeutics as a new class of medicines, today announced that its President and Chief Executive Officer, Douglas E. Williams, Ph.D., will participate in a fireside chat at the Evercore ISI 3rd Annual HealthCONx Conference.

Key Points:

CAMBRIDGE, Mass., Nov. 23, 2020 (GLOBE NEWSWIRE) -- Codiak BioSciences, Inc. (NASDAQ: CDAK), a clinical-stage company focused on pioneering the development of exosome-based therapeutics as a new class of medicines, today announced that its President and Chief Executive Officer, Douglas E. Williams, Ph.D., will participate in a fireside chat at the Evercore ISI 3rd Annual HealthCONx Conference.
Details are as follows:
A live webcast of the fireside chat will be available on the Investors & Media section of the Codiak website at www.codiakbio.com .
An archived replay will be available for approximately 90 days following the fireside chat.
Codiak has utilized its engEx Platform to generate a deep pipeline of engineered exosomes aimed at treating a broad range of disease areas, spanning oncology, neuro-oncology, neurology, neuromuscular disease and infectious disease.

Caraway Therapeutics Receives Research Grant from The Michael J. Fox Foundation to Further Investigate the Function of the Lysosomal Ion Channel TMEM175 and Gene Variants Linked to Parkinson’s Disease

Retrieved on:

Wednesday, November 18, 2020

This latest grant builds on Caraways drug discovery research focused on the role of lysosomal function and autophagy in neurodegenerative and rare diseases to further investigate the role of TMEM175, a lysosomal ion channel genetically implicated in Parkinsons disease (PD).

Key Points:

This latest grant builds on Caraways drug discovery research focused on the role of lysosomal function and autophagy in neurodegenerative and rare diseases to further investigate the role of TMEM175, a lysosomal ion channel genetically implicated in Parkinsons disease (PD).
Recent genetic data from multiple studies indicate that variants in TMEM175 impact both age of onset and incidence of PD.
Decreased TMEM175 function reduces lysosomal efficiency in neuronal cells, which is strongly associated with Parkinsons disease.
Mutations in TMEM175 are clear risk factors for the development of Parkinsons disease, added Magdalene Moran, Chief Scientific Officer at Caraway Therapeutics.

Evox Therapeutics announces launch of strategic collaboration with the University of Oxford

Retrieved on:

Tuesday, November 17, 2020

Branches of biology, Exosome, Vesicles

OXFORD, England, Nov. 17, 2020 /PRNewswire/ -- Evox Therapeutics Ltd ('Evox' or the 'Company'), a leading exosome therapeutics company, is pleased to announce the launch of a collaboration focused on rare diseases with the University of Oxford's Oxford-Harrington Rare Disease Centre embedded within the Department of Paediatrics.

Key Points:

OXFORD, England, Nov. 17, 2020 /PRNewswire/ -- Evox Therapeutics Ltd ('Evox' or the 'Company'), a leading exosome therapeutics company, is pleased to announce the launch of a collaboration focused on rare diseases with the University of Oxford's Oxford-Harrington Rare Disease Centre embedded within the Department of Paediatrics.
The collaboration will run over three years and will capitalise on the world-class exosome research environment in Oxford, leveraging exosome therapeutics expertise and resources from both Evox and the University to drive innovation within rare disease drug development.
The Oxford-Harrington Rare Disease Centre an affiliation between the University of Oxford and Harrington Discovery Institute is a global leader incutting-edge rare disease translational research.
Through this collaboration, the parties will stimulate and support innovative approaches to identify and develop exosome therapeutics for the treatment of rare diseases.

CUSABIO Exosome Isolation Kit, A Great Exosome Research Tool

Retrieved on:

Friday, November 13, 2020

Branches of biology, Vesicles, Exosome

HOUSTON, Nov. 13, 2020 /PRNewswire-PRWeb/ --In 2019, the team at CUSABIO developed the first commercial Exosome Isolation Kit by affinity purification.

Key Points:

HOUSTON, Nov. 13, 2020 /PRNewswire-PRWeb/ --In 2019, the team at CUSABIO developed the first commercial Exosome Isolation Kit by affinity purification.
CUSABIO exosome isolation kit can extract exosome from various sample types and cells with high purity and yield.
No large-scale equipment required.And the exosomes extracted by CUSABIO Exosome Isolation Kit are comparableto ultracentrifugation with High Purity and High Yield.
It is also one of the reasons why CUSABIO developed the Exosome isolation kit.

Capricor Therapeutics Reports Third Quarter 2020 Financial Results and Provides Corporate Update

Retrieved on:

Thursday, November 12, 2020

Branches of biology, Exosome, Vesicles, Forward-looking statement

The Companys development and achievements in the third quarter have been encouraging on multiple levels.

Key Points:

The Companys development and achievements in the third quarter have been encouraging on multiple levels.
We are now leveraging thought leaders and our own expertise to direct the development of exosome-based vaccines and exosome-based therapeutics.
Additionally, in the third quarter of 2020, Capricor raised approximately $2.0 million in net proceeds at an average price of approximately $5.87 per share under its at-the-market offering program.
All forward-looking statements in this press release are based on information available to Capricor as of the date hereof, and Capricor assumes no obligation to update these forward-looking statements.

Capricor Therapeutics Announces Positive Preclinical Data for Multivalent Exosome-mRNA Vaccine For COVID-19

Retrieved on:

Monday, November 9, 2020

Branches of biology, Biology, Life sciences, RNA, Immune system, Gene expression, Molecular genetics, Exosome, Vesicles, RNA vaccine, Messenger RNA, Polyclonal antibodies

This study represents a major step forward for our joint effort to develop exosome-based therapeutics.

Key Points:

This study represents a major step forward for our joint effort to develop exosome-based therapeutics.
Key findings of the pre-clinical study in mice include:
Development of safe, non-toxic exosome formulation capable of delivering functional mRNA in vitro and in vivo.
Creation of a multiplexed exosome-RNA vaccine that expresses viral antigens engineered to induce cellular immunity and antibody responses to multiple proteins of SARS-CoV-2.
Validation that an exosome mRNA vaccine can induce:
Persistent cellular immune responses to the SARS-CoV-2 N and S proteins.

Evelo Biosciences Presents New Preclinical Data for Anti-Tumor Effects of Orally Delivered Microbial Extracellular Vesicles at the SITC 35th Anniversary Annual Meeting

Retrieved on:

Monday, November 9, 2020

Branches of biology, Clinical medicine, Medicine, Vesicles, Cell biology, Oncology, Cancer immunotherapy, Cells, Extracellular vesicle, Chemotherapy, Checkpoint inhibitor

The data show that orally administered EDP1908 had anti-tumor effects that surpassed both checkpoint inhibitors and orally delivered microbial strains in preclinical models.

Key Points:

The data show that orally administered EDP1908 had anti-tumor effects that surpassed both checkpoint inhibitors and orally delivered microbial strains in preclinical models.
Today, we are unveiling new foundational data showing that an orally administered bacterial extracellular vesicle (EV) has striking preclinical anti-tumor effects without systemic distribution.
These data suggest that EVs of appropriately selected microbes have the potential to drive an entirely new type of I/O therapy by engaging SINTAX.
Evelo Biosciences is a clinical stage biotechnology company developing orally delivered medicines that act on SINTAX, the small intestinal axis, with systemic therapeutic effects.